Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering Monte Rosa Therapeutics’ cutting-edge science is challenging enough—poring over hundreds of pages of risk factors, pipeline updates, and equity offerings in each filing can feel impossible. Whether you are tracking Monte Rosa Therapeutics insider trading Form 4 transactions for signs of management confidence or need clarity on new clinical trial data buried deep in an 8-K, the details matter.
Stock Titan’s AI-powered summaries turn dense biotech disclosures into plain language. Instantly see cash-runway figures from the latest Monte Rosa Therapeutics quarterly earnings report 10-Q filing, receive Monte Rosa Therapeutics Form 4 insider transactions real-time, and access pipeline-specific risk highlights no spreadsheet work required. Our engine was built for questions investors actually ask, like “How is Monte Rosa funding Phase 1 studies?” or “What does the newest Monte Rosa Therapeutics proxy statement executive compensation reveal about R&D incentives?”
You’ll find every form in one place—10-Ks, 10-Qs, 8-Ks, S-3s, and more—with real-time filing alerts and expert annotations. Dive into a Monte Rosa Therapeutics annual report 10-K simplified to understand trial timelines, or review a concise note that has Monte Rosa Therapeutics 8-K material events explained the moment results post. Need deeper analysis? Our dashboards link revenue trends straight to pipeline catalysts, offering a quick Monte Rosa Therapeutics earnings report filing analysis. From understanding Monte Rosa Therapeutics SEC documents with AI to monitoring Monte Rosa Therapeutics executive stock transactions Form 4, Stock Titan equips you to act on data, not dig for it. Monte Rosa Therapeutics SEC filings explained simply—finally, biotech disclosure without the headache.
Monte Rosa Therapeutics (GLUE) reported Q3 2025 results. Collaboration revenue was $12.8 million, up from $9.2 million a year ago. Operating expenses were $45.7 million, driven by R&D of $36.7 million and G&A of $9.1 million, resulting in a net loss of $27.1 million for the quarter.
Year to date, the company recorded net income of $7.5 million, reflecting recognition tied to collaboration activity, including completion of the $150.0 million upfront under the 2024 Novartis license. Cash, cash equivalents and marketable securities totaled $391.3 million as of September 30, 2025, with positive operating cash flow of $20.2 million for the nine-month period.
Deferred revenue was $136.7 million (current $24.8 million; noncurrent $111.9 million), supported by major partnerships. The Sept. 2025 Novartis agreement added a $120.0 million upfront (with up to $5.4 billion in potential milestones), of which $0.4 million has been recognized and $119.6 million deferred. Under the Roche collaboration, $44.9 million has been recognized to date with $17.1 million remaining deferred. Management expects existing liquidity to fund operations for at least 12 months.
Monte Rosa Therapeutics (GLUE) furnished an update on operations, announcing it has reported financial results for the quarter ended September 30, 2025. The full details are contained in a press release furnished as Exhibit 99.1.
The company also posted a revised corporate presentation to the Presentations section of its website on November 6, 2025. Information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference unless expressly stated.
Monte Rosa Therapeutics, Inc. received a joint Schedule 13G filing showing that Dimension Capital I, L.P. and affiliated reporting persons collectively beneficially hold 4,757,563 shares of the issuer's common stock, representing 7.7% of the class. The filing lists the reporting persons as Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, Dimension Capital I, L.P. and individuals Adam Goulburn, Zavain Dar, and Nan Li. The cover information states the ownership percentages are calculated using 61,759,350 outstanding shares reported by the issuer as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the disclosed shares and certify the shares were not acquired to change control of the company.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,725,000 shares of Monte Rosa Therapeutics common stock, representing 6.1% of the class. The reporting persons state they have sole voting and sole dispositive power over these shares and that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The percentage is calculated using 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control; signatures appear for Avoro and for Behzad Aghazadeh.
FAQ
What is the current stock price of Monte Rosa Therapeutics (GLUE)?
What is the market cap of Monte Rosa Therapeutics (GLUE)?
